Literature DB >> 25405499

Hyperglycemic clamp and oral glucose tolerance test for 3-year prediction of clinical onset in persistently autoantibody-positive offspring and siblings of type 1 diabetic patients.

Eric V Balti1, Evy Vandemeulebroucke, Ilse Weets, Ursule Van De Velde, Annelien Van Dalem, Simke Demeester, Katrijn Verhaeghen, Pieter Gillard, Christophe De Block, Johannes Ruige, Bart Keymeulen, Daniel G Pipeleers, Katelijn Decochez, Frans K Gorus.   

Abstract

CONTEXT AND
OBJECTIVE: In preparation of future prevention trials, we aimed to identify predictors of 3-year diabetes onset among oral glucose tolerance test (OGTT)- and hyperglycemic clamp-derived metabolic markers in persistently islet autoantibody positive (autoAb(+)) offspring and siblings of patients with type 1 diabetes (T1D).
DESIGN: The design is a registry-based study.
SETTING: Functional tests were performed in a hospital setting. PARTICIPANTS: Persistently autoAb(+) first-degree relatives of patients with T1D (n = 81; age 5-39 years). MAIN OUTCOME MEASURES: We assessed 3-year predictive ability of OGTT- and clamp-derived markers using receiver operating characteristics (ROC) and Cox regression analysis. Area under the curve of clamp-derived first-phase C-peptide release (AUC(5-10 min); min 5-10) was determined in all relatives and second-phase release (AUC(120-150 min); min 120-150) in those aged 12-39 years (n = 62).
RESULTS: Overall, the predictive ability of AUC(5-10 min) was better than that of peak C-peptide, the best predictor among OGTT-derived parameters (ROC-AUC [95%CI]: 0.89 [0.80-0.98] vs 0.81 [0.70-0.93]). Fasting blood glucose (FBG) and AUC(5-10 min) provided the best combination of markers for prediction of diabetes within 3 years; (ROC-AUC [95%CI]: 0.92 [0.84-1.00]). In multivariate Cox regression analysis, AUC(5-10 min)) (P = .001) was the strongest independent predictor and interacted significantly with all tested OGTT-derived parameters. AUC(5-10 min) below percentile 10 of controls was associated with 50-70% progression to T1D regardless of age. Similar results were obtained for AUC(120-150 min).
CONCLUSIONS: Clamp-derived first-phase C-peptide release can be used as an efficient and simple screening strategy in persistently autoAb(+) offspring and siblings of T1D patients to predict impending diabetes.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25405499     DOI: 10.1210/jc.2014-2035

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  6 in total

1.  Relationship between glycaemic variability and hyperglycaemic clamp-derived functional variables in (impending) type 1 diabetes.

Authors:  Annelien Van Dalem; Simke Demeester; Eric V Balti; Katelijn Decochez; Ilse Weets; Evy Vandemeulebroucke; Ursule Van de Velde; An Walgraeve; Nicole Seret; Christophe De Block; Johannes Ruige; Pieter Gillard; Bart Keymeulen; Daniel G Pipeleers; Frans K Gorus
Journal:  Diabetologia       Date:  2015-09-26       Impact factor: 10.122

2.  A little help from residual β cells has long-lasting clinical benefits.

Authors:  Anna Lam; Colin Dayan; Kevan C Herold
Journal:  J Clin Invest       Date:  2021-02-01       Impact factor: 14.808

3.  Preexisting insulin autoantibodies predict efficacy of otelixizumab in preserving residual β-cell function in recent-onset type 1 diabetes.

Authors:  Simke Demeester; Bart Keymeulen; Leonard Kaufman; Annelien Van Dalem; Eric V Balti; Ursule Van de Velde; Patrick Goubert; Katrijn Verhaeghen; Howard W Davidson; Janet M Wenzlau; Ilse Weets; Daniel G Pipeleers; Frans K Gorus
Journal:  Diabetes Care       Date:  2015-01-12       Impact factor: 19.112

4.  Prediction of Impending Type 1 Diabetes through Automated Dual-Label Measurement of Proinsulin:C-Peptide Ratio.

Authors:  Annelien Van Dalem; Simke Demeester; Eric V Balti; Bart Keymeulen; Pieter Gillard; Bruno Lapauw; Christophe De Block; Pascale Abrams; Eric Weber; Ilse Vermeulen; Pieter De Pauw; Daniël Pipeleers; Ilse Weets; Frans K Gorus
Journal:  PLoS One       Date:  2016-12-01       Impact factor: 3.240

5.  Time to Peak Glucose and Peak C-Peptide During the Progression to Type 1 Diabetes in the Diabetes Prevention Trial and TrialNet Cohorts.

Authors:  Michael G Voss; David D Cuthbertson; Mario M Cleves; Ping Xu; Carmella Evans-Molina; Jerry P Palmer; Maria J Redondo; Andrea K Steck; Markus Lundgren; Helena Larsson; Wayne V Moore; Mark A Atkinson; Jay M Sosenko; Heba M Ismail
Journal:  Diabetes Care       Date:  2021-08-06       Impact factor: 17.152

Review 6.  Cause or effect? A review of clinical data demonstrating beta cell dysfunction prior to the clinical onset of type 1 diabetes.

Authors:  Emily K Sims; Linda A DiMeglio
Journal:  Mol Metab       Date:  2019-09       Impact factor: 7.422

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.